Berberine vs metformin vs a GLP-1: what each does to weight and glucose

Reviewed 18 sourcesPublished by PepVault

People lost 14.9% of body weight on a GLP-1, about 2% on metformin, under 1 kg on berberine. Metformin is not a GLP-1. Weight and HbA1c trials, side by side.

A man in a burgundy t-shirt tossing a vegetable stir-fry in a wok
Last reviewed
Sources
18
Questions
7
Compounds
4

The short answer

For weight, a GLP-1 wins by a wide margin: semaglutide took off 14.9% of body weight in 68 weeks, against 2.4% on placebo. Metformin averaged about 2%, and berberine under 1 kg against control. For HbA1c, metformin and semaglutide each cut 1.4 to 1.8 points more than placebo in their label trials; berberine about 0.7. Metformin is not a GLP-1.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Large randomized phase 3 trials and FDA labels for semaglutide, tirzepatide and metformin; for berberine, many small randomized trials pooled in meta-analyses (mostly from China), one 337-person blinded trial and one small head-to-head pilot with metformin.

A man in a burgundy t-shirt tossing a vegetable stir-fry in a wok

Which one lowers weight and blood sugar the most?

On weight, the GLP-1 drugs are in a different league. On blood sugar, metformin holds its own against them, and berberine does about half as much. HbA1c is the blood test that reads your average blood sugar over the past two to three months; a drop of 1 point means, for example, going from 8.4% to 7.4%.

TrialWho, how longWeight: drug vs placeboHbA1c: drug vs placebo
Semaglutide 2.4 mg, STEP 131,961 adults with obesity, no diabetes, 68 weeks-14.9% vs -2.4% (-15.3 kg vs -2.6 kg)-0.4 vs -0.2 points, from 5.7%17
Semaglutide 2.4 mg, STEP 241,210 adults with obesity and type 2 diabetes, 68 weeks-9.6% vs -3.4%-1.6 vs -0.4 points (1.2 more than placebo)17
Semaglutide 1 mg, the Ozempic label1388 adults with type 2 diabetes, 30 weeks-4.7 kg vs -1.2 kg-1.6 vs -0.1 points (1.4 more than placebo)
Tirzepatide 15 mg, SURMOUNT-152,539 adults with obesity, no diabetes, 72 weeks-20.9% vs -3.1%Not the endpoint
Metformin up to 2,550 mg, the label2286 adults with obesity and type 2 diabetes, 29 weeks-1.4 lb vs -2.4 lb (no edge over placebo)-1.4 vs +0.4 points (1.8 more than placebo)
Metformin 850 mg twice daily, DPP7Adults at high risk of diabetes, about 2 years-2.1% vs 0.0%Not the endpoint; new diabetes cut 31%6
Berberine, pooled1123 randomized trials in adults0.88 kg more than control (pooled difference)Not pooled here
Berberine 1 g, BRAVO13337 adults with obesity and fatty liver, no diabetes, 6 months-1.8 kg vs -1.9 kg (no difference)No difference, from 5.7%; 38% had prediabetes
Berberine, pooled946 randomized trials in type 2 diabetesNot the endpoint0.73 points more than control (pooled difference)

Each pair is drug against placebo in the same trial; the two pooled berberine rows are already the difference from control. These are different trials in different people, so read the rows as sizes, not as a race run on one track. The direct comparisons that exist point the same way: in 36 adults with new type 2 diabetes, berberine and metformin at 0.5 g three times a day lowered blood sugar about equally over 3 months, HbA1c 9.5% to 7.5% on berberine and 9.15% to 7.72% on metformin10. That trial was a small pilot. We found no trial that put berberine against a GLP-1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's bloodwork log records HbA1c and fasting glucose, so the 3-month panel sits beside the one before it.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Is metformin a GLP-1?

No. Metformin is a biguanide, a different drug class: it makes the liver release less sugar into the blood, lets less sugar in from the gut and helps the body respond to insulin2. It does nudge your own GLP-1 up, though. In a randomized trial of 173 people without diabetes, metformin raised blood GLP-1 by 23% over 18 months against placebo, and the rise did not depend on weight or blood-sugar changes8.

A GLP-1 drug works at another scale. GLP-1 is a gut hormone released after a meal that tells the pancreas to make insulin, holds back glucagon and slows the stomach a little1. The body's own GLP-1 is broken down fast by an enzyme called DPP-4. Semaglutide shares 94% of its sequence with human GLP-1 and is built to resist that enzyme, so its half-life is about a week1. That is why its effect on appetite and weight dwarfs a 23% rise in your own hormone.

Is berberine really "nature's Ozempic"?

Not on the numbers. Berberine is a yellow alkaloid from plants such as barberry, sold as a supplement. Pooled across 23 randomized trials, it lowered body weight by 0.88 kg (about 2 lb) more than control11. An older pool of 12 trials found 2.07 kg, the "4 to 5 pounds" figure many pages quote12. Then came a large blinded trial: BRAVO gave 337 adults with obesity 1 g a day or placebo for 6 months, and both groups lost the same weight, 1.8 kg on berberine and 1.9 kg on placebo13. Deep belly fat and liver fat, the trial's main targets, did not differ either.

Where berberine earns its reputation is blood sugar and cholesterol. In people with type 2 diabetes it lowered HbA1c by 0.73 points across 46 trials, alone or added to standard treatment9, and across 14 placebo-controlled trials it cut LDL cholesterol by 0.46 mmol/L, about 18 mg/dL14. BRAVO confirmed an LDL drop, 7.7 mg/dL more than placebo, but in people without diabetes (average HbA1c 5.7%, 38% with prediabetes), HbA1c and fasting glucose did not differ from placebo13. So berberine's blood-sugar effect shows in type 2 diabetes, not in people without it.

Lab note: berberine raised the gut's own GLP-1 release in rats and in cultured human gut cells16; that has not been shown to matter for weight in people, as the trials above show. Most berberine trials were run in China14.

How much weight does metformin take off?

A little, and it lasts. In the Diabetes Prevention Program, 3,234 adults at high risk of diabetes took metformin 850 mg twice a day, placebo or a lifestyle program6. Over the 2-year blinded period, the metformin group lost 2.1% of body weight against almost none on placebo, and the loss held at about 2% through 10 years of follow-up, larger in people who kept taking it7. Metformin cut new cases of diabetes by 31%; the lifestyle program cut them by 58%6.

In the label's 29-week diabetes trial, people on metformin lost 1.4 lb against 2.4 lb on placebo, so no weight advantage at all, while HbA1c fell 1.4 points on metformin and rose 0.4 on placebo2. Metformin is a blood-sugar drug that happens to be weight-neutral or slightly helpful. It is not a weight-loss drug.

How big is a GLP-1's effect next to the other two?

On weight, counted beyond placebo or control, about six times metformin's effect and fourteen times berberine's. In STEP 1, semaglutide 2.4 mg took off 15.3 kg on average in 68 weeks, against 2.6 kg on placebo, and half the people on it lost 15% or more of their body weight3. In people who also had type 2 diabetes, the loss was smaller, 9.6% against 3.4%4. Tirzepatide, which acts on GLP-1 and a second gut hormone (GIP), went to 20.9% at its top dose in 72 weeks5.

On HbA1c, semaglutide 1 mg on its own lowered it 1.6 points in 30 weeks, and 73% of people at 0.5 mg reached an HbA1c under 7%1. That is in metformin's range, and the two are not rivals: in the label's 56-week trial against sitagliptin, 94% of people took their study drug on top of metformin1. How the doses step up week by week is in our semaglutide and tirzepatide week-by-week guides.

What do they feel like, and what mixes badly?

All three land in the gut first. On metformin in the label trial, diarrhea hit 53% against 12% on placebo and nausea 26% against 8%; diarrhea led 6% to stop2. The label starts low and steps up, with meals, for this reason. On semaglutide, nausea and diarrhea were the most common effects, typically mild to moderate and passing; 4.5% stopped for stomach reasons against 0.8% on placebo3. Berberine's stomach effects were milder, 2 to 23% of people against 2 to 15% on placebo, with no serious adverse events in 16 trials14.

The interaction that matters is berberine's. In healthy men, 300 mg three times a day for two weeks slowed three liver enzymes that clear many prescription drugs (CYP2D6, CYP2C9 and CYP3A4); one test drug's blood level rose 40%15. Berberine also lowers blood sugar further on top of diabetes medicines9. Metformin's label carries a rare but serious warning, lactic acidosis, with the risk higher with poor kidney function, heavy drinking or age 65 and over2. Semaglutide's and tirzepatide's labels carry a boxed warning of their own: thyroid C-cell tumors in rodents, of unknown relevance to people, so they are not used by anyone with a personal or family history of medullary thyroid cancer or MEN 2118. Starting metformin or a GLP-1, or adding berberine to either, is a decision for your doctor, who can check your kidneys and your other medicines first.

Commonly reported: on berberine, constipation, loose stools or nausea14; on metformin, loose stools that settle as the dose climbs slowly; on a GLP-1, early fullness, nausea after large or fatty meals, and much quieter thoughts about food.

When to get help If you take insulin or another diabetes medicine and add berberine, shakiness, sweating or confusion that does not clear after a sugary snack is a reason to get medical help the same day.

How do you tell whether yours is working?

HbA1c reflects about three months of blood sugar, so a change shows at about 3 months, the length of the head-to-head trial above10. Weight trends need weeks, not days. A fair test is one change at a time, measured the same way before and after.

  • Get an HbA1c and a fasting glucose before you start, and repeat them at about 3 months.
  • Weigh at the same time of day, a few times a week, and judge the 4-week trend rather than any single morning.

PepVault's bloodwork log records HbA1c and fasting glucose, so the 3-month panel sits beside the one before it. Log it in PepVault

PepVault logs berberine, metformin or a GLP-1 in your protocol with a daily or weekly reminder, and keeps your weigh-ins in the weight log. Set reminders in PepVault

Track it in the app

Sources

  1. Ozempic (semaglutide) injection, prescribing information, sections 12 and 14. Novo Nordisk. DailyMed SPL version 20, Jun 2026. dailymed.nlm.nih.gov
  2. Metformin hydrochloride tablets, prescribing information, sections 5, 6, 12 and 14. PD-Rx Pharmaceuticals. DailyMed SPL version 20, Nov 2026. dailymed.nlm.nih.gov
  3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
  4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021. PubMed 33667417
  5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
  6. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). N Engl J Med. 2002. PubMed 11832527
  7. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012. PubMed 22442396
  8. Preiss D et al. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes Metab. 2017. PubMed 27862873
  9. Guo J et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Oxid Med Cell Longev. 2021. PubMed 34956436
  10. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008. PubMed 18442638
  11. Elahi Vahed I et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. Int J Obes. 2026. PubMed 41310257
  12. Asbaghi O et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020. PubMed 32690176
  13. Lei L et al. Berberine and adiposity in diabetes-free individuals with obesity and MASLD: a randomized clinical trial (BRAVO). JAMA Netw Open. 2026. PubMed 41543854
  14. Blais JE, Huang X, Zhao JV. Overall and sex-specific effect of berberine for the treatment of dyslipidemia in adults: a systematic review and meta-analysis of randomized placebo-controlled trials. Drugs. 2023. PubMed 36941490
  15. Guo Y et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012. PubMed 21870106
  16. Yu Y et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol. 2010. PubMed 19945441
  17. Wegovy (semaglutide) injection, prescribing information, section 14, Table 13 (STEP 1 and STEP 2 HbA1c). Novo Nordisk. DailyMed SPL version 19, Jun 2026. dailymed.nlm.nih.gov
  18. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, boxed warning. DailyMed. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo